Dynorphin A (trifluoroacetate salt) (Synonyms: Dynorphin A (1-17)) |
Catalog No.GC52500
One-Click Copy Product Info
|
Dynorphin A (trifluoroacetate salt) es un péptido opioide endógeno que activa el canal receptor huérfano XOR1-K+ , con un valor EC50 de 45nM
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Dynorphin A (trifluoroacetate salt) es un péptido opioide endógeno que activa el canal receptor huérfano XOR1-K+ , con un valor EC50 de 45nM [1]. Dynorphin A (trifluoroacetate salt) puede unirse y activar a todos los familias de receptores opioides, regulando flujo iónico de la membranan de las neuronas[2]. Dynorphin A (trifluoroacetate salt) se ha aplicado en sestudios relacionados con la necesidad de las drogas ty la adición, así como en la regulación de las funciones neuronales[3].
In vitro, el tratamiento con Dynorphin A (trifluoroacetate salt) a 10μM durante 4 horas indujo la activación de la caspase-3 en las células neuronales estriatales del ratón y aumentó el nivel de citocromo c liberado de mitocondrias[4]. El tratamiento con Dynorphin A (trifluoroacetate salt) (10μM) mientras 16 horas puede provocar una fuete actividad de respeusta de migración en las células HEK293 que expresan Mac-1[5]. El tratamiento con 100μM de Dynorphin A (trifluoroacetate salt) durante 96 horas indujo la muerte propios de las neuronas la médula espinal de ratón [6]. El tratamiento con Dynorphin A (trifluoroacetate salt) a 10μM durante 48 horas redujo la viabilidad de las células U2OS, causando disfunción mitocondrial y factores reguladores mitocondriales clave que regulan a la baja, incluidos PGC-1α, Nrf1 y TFAM[7]. El tratamiento con Dynorphin A (trifluoroacetate salt) a 1μM durante 1 hora inhibió la translocación nuclear de NF-κB/p65 en células THP-1 estimuladas por lipopolysaccharide (LPS) [8].
References:
[1] Zhang S, Yu L. Identification of dynorphins as endogenous ligands for an opioid receptor-like orphan receptor[J]. Journal of Biological Chemistry, 1995, 270(39): 22772-22776.
[2] Zhang S, Tong Y, Tian M, et al. Dynorphin A (trifluoroacetate salt) as a potential endogenous ligand for four members of the opioid receptor gene family[J]. The Journal of pharmacology and experimental therapeutics, 1998, 286(1): 136-141.
[3] Shippenberg T S, Zapata A, Chefer V I. Dynorphin A (trifluoroacetate salt)nd the pathophysiology of drug addiction[J]. Pharmacology & therapeutics, 2007, 116(2): 306-321.
[4] Singh I N, Goody R J, Goebel S M, et al. Dynorphin A (trifluoroacetate salt) (1–17) induces apoptosis in striatal neurons in vitro through AMPA/kainate receptor-mediated cytochrome c release and caspase-3 activation[J]. Neuroscience, 2003, 122(4): 1013.
[5] Podolnikova N P, Brothwell J A, Ugarova T P. The opioid peptide Dynorphin A (trifluoroacetate salt) induces leukocyte responses via integrin Mac-1 (αMβ2, CD11b/CD18)[J]. Molecular pain, 2015, 11: s12990-015-0027-0.
[6] Hauser K F, Knapp P E, Turbek C S. Structure–activity analysis of Dynorphin A (trifluoroacetate salt) toxicity in spinal cord neurons: intrinsic neurotoxicity of Dynorphin A (trifluoroacetate salt) and its carboxyl-terminal, nonopioid metabolites[J]. Experimental neurology, 2001, 168(1): 78-87.
[7] Dai Y, Zhang J, Peng Y, et al. Dynorphin A (trifluoroacetate salt) Impairs Mitochondrial Biogenesis in Osteosarcoma Cells by Increasing SP‐1[J]. Journal of Biochemical and Molecular Toxicology, 2025, 39(9): e70451.
[8] Fazalul Rahiman S S, Morgan M, Gray P, et al. Dynorphin 1-17 and its N-terminal biotransformation fragments modulate lipopolysaccharide-stimulated nuclear factor-kappa B nuclear translocation, interleukin-1beta and tumor necrosis factor-alpha in differentiated THP-1 cells[J]. PLoS One, 2016, 11(4): e0153005.
| Experimentos celulares [1]: | |
Líneas celulares | Células U2OS |
Método de preparación | Las células U2OS se cultivaron en medio DMEM, que se complementó con un 10% de suero bovino fetal (FBS), L-glutamine y 1% de penicillin/streptomycin. Las células fueron cultivadas en condiciones de 37°C y 5% de CO2. Se inocularon 3000 células U2OS en cada pozo de una placa de 96 pozos. Las células se tartaron con Dynorphin A (trifluoroacetate salt) a concentraciones de 0.1, 0.5, 1, 5, 10, 50 y 100μM durante 48 horas. Se añadieron 10μl de reactivo CCK-8 a cada pozo y se incubaron durante 2 horas. Luego, el valor de absorbancia se midió a 450nm. |
Condiciones de reacción | 0.1, 0.5, 1, 5, 10, 50 y 100μM; 48h |
Áreas de aplicación | El tratamiento con Dynorphin A (trifluoroacetate salt) redujo la biabilidad de las células U2OS de una manera dependiente de la dosis. |
References: | |
| Cas No. | SDF | ||
| Sinónimos | Dynorphin A (1-17) | ||
| Canonical SMILES | O=C(N[C@@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](C(O)=O)CCC(N)=O)=O)=O)[C@@H](NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCC1)N1C([C@H](CCCNC(N)=N)NC([C@@]([C@@H](C)CC)([H])NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@@H](NC(CNC(CNC([C@@H](N)CC2=CC=C(O)C=C2)=O)=O)=O)CC3=CC=CC=C3)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC4=CNC5=CC=CC=C45.FC(F)(C(O)=O)F | ||
| Formula | C99H155N31O23 ? XCF3COOH | M.Wt | 2147.5 |
| Solubility | DMF: 30 mg/mL,DMSO: 30 mg/mL,PBS (pH 7.2): 5 mg/mL | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 465.7 μL | 2.3283 mL | 4.6566 mL |
| 5 mM | 93.1 μL | 465.7 μL | 931.3 μL |
| 10 mM | 46.6 μL | 232.8 μL | 465.7 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A crystalline solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)